Study ID,first author,study design,publication date,primary series vaccine,booster vaccine,historyofCOVID ,reference group,timing_of_dose_days,outcome_detail,outcome_category,country,population_detail,population_category,VE,LCL,UCL,variant_sequenced,variant_context,max duration follow-up
7,Andrews,Test-negative case-control,17Dec2021,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,complete vaccination with 2 doses ≥140 days prior,14+,symptomatic disease,symptomatic,England,50+ years,≥ 50 years,89.1,88.3,89.9,,delta,~7.5 weeks
7,Andrews,Test-negative case-control,17Dec2021,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,symptomatic disease,symptomatic,England,50+ years,≥ 50 years,93.8,93.3,94.3,,delta,~7.5 weeks
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,18+ years,general pop,62.7,62.0,63.4,omicron,omicron,~14 weeks
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,10+ weeks,symptomatic disease,symptomatic,England,18+ years,general pop,44.1,42.2,45.9,omicron,omicron,~14 weeks
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,18+ years,general pop,95.4,95.2,95.7,delta,delta,~14 weeks
11,Andrews,Test-negative case-control,14Jan2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,10+ weeks,symptomatic disease,symptomatic,England,18+ years,general pop,88.5,87.0,89.7,delta,delta,~14 weeks
12,Berec,Retrospective cohort,12Dec2021,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,complete vaccination with 2 doses ≥6-8 months prior,7+,infection,infection,Czech Republic,18+ years,general pop,82.0,68.0,90.0,,delta,~8 weeks
28,Spensley,Prospective cohort,26Jan2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,infection,infection,UK,end stage kidney disease patients,end stage kidney disease patients,47.0,2.0,70.0,omicron,omicron,~15 weeks
49,Baum,Retrospective cohort,06Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,70+ years,≥ 70 years,98.0,91.0,99.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks
49,Baum,Retrospective cohort,06Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,70+ years,≥ 70 years,88.0,78.0,93.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks
49,Baum,Retrospective cohort,06Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),excluded,unvaccinated individuals,61+,ICU admission,severe,Finland,70+ years,≥ 70 years,96.0,71.0,99.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks
49,Baum,Retrospective cohort,06Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,70+ years,≥ 70 years,84.0,-16.0,98.0,,delta,~13 weeks
49,Baum,Retrospective cohort,06Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,70+ years,≥ 70 years,99.0,91.0,100.0,,omicron,~20.5 weeks
49,Baum,Retrospective cohort,06Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,70+ years,≥ 70 years,86.0,75.0,92.0,,omicron,~20.5 weeks
53,Stowe,Test-negative case-control,24Mar2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,7-13,hospitalization,severe,UK,18-64 years,18-64 years,83.0,78.0,85.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,105+,hospitalization,severe,UK,18-64 years,18-64 years,39.0,18.0,58.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,14-28,ICU admission,severe,UK,18-64 years,18-64 years,98.0,90.0,99.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,70-98,ICU admission,severe,UK,18-64 years,18-64 years,90.0,77.0,98.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,7-13,hospitalization,severe,UK,65+ years,≥ 65 years,96.0,78.0,98.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,105+,hospitalization,severe,UK,65+ years,≥ 65 years,82.0,77.0,84.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,7-13,ICU admission,severe,UK,65+ years,≥ 65 years,97.0,36.0,100.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,105+,ICU admission,severe,UK,65+ years,≥ 65 years,92.0,82.0,96.0,,omicron,~22 weeks
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,82.9,81.9,83.8,,delta,~20 weeks
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,95.1,93.8,96.2,,delta,~20 weeks
72,Vokó,Retrospective cohort,22Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,98.4,96.5,99.3,,delta,~20 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,Brazil,18+ years,general pop,42.8,42.1,43.5,,omicron,2 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,13+ weeks,symptomatic disease,symptomatic,Brazil,18+ years,general pop,4.9,2.7,7.0,,omicron,~21 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,severe disease,severe,Brazil,18+ years,general pop,89.9,88.9,90.7,,omicron,2 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,13+ weeks,severe disease,severe,Brazil,18+ years,general pop,80.2,77.9,82.2,,omicron,~21 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,Scotland,18+ years,general pop,49.0,45.3,52.4,,omicron,2 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,13+ weeks,symptomatic disease,symptomatic,Scotland,18+ years,general pop,18.2,7.2,28.0,,omicron,~22 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,severe disease,severe,Scotland,18+ years,general pop,81.8,55.0,92.6,,omicron,2 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,13+ weeks,severe disease,severe,Scotland,18+ years,general pop,93.4,69.6,98.6,,omicron,~22 weeks
80,Kirsebom,Test-negative case-control,01May2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,14-34,symptomatic disease,symptomatic,UK,40-64 years,40-64 years,63.8,63.0,64.5,omicron,omicron,~3 weeks
80,Kirsebom,Test-negative case-control,01May2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,105+,symptomatic disease,symptomatic,UK,40-64 years,40-64 years,30.6,26.8,34.3,omicron,omicron,~20 weeks
80,Kirsebom,Test-negative case-control,01May2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,14-34,symptomatic disease,symptomatic,UK,65+ years,≥ 65 years,58.1,51.6,63.8,omicron,omicron,~3 weeks
80,Kirsebom,Test-negative case-control,01May2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,105+,symptomatic disease,symptomatic,UK,65+ years,≥ 65 years,23.1,15.1,30.5,omicron,omicron,~20 weeks
80,Kirsebom,Test-negative case-control,01May2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,7+,hospitalization,severe,UK,65+ years,≥ 65 years,90.9,88.7,92.7,omicron,omicron,~20 weeks
80,Kirsebom,Test-negative case-control,01May2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated individuals,7+,hospitalization,severe,UK,65+ years,≥ 65 years,93.9,92.8,94.9,delta,delta,~15 weeks
89,Marra,Retrospective cohort,27May2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of AZD1222,14+,infection,infection,Brazil,HCW,HCW,60.5,44.9,72.4,,delta,~11 weeks
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,1-28,infection,infection,UK,18+ years,general pop,49.2,48.4,50.0,,delta,~11 weeks
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,infection,infection,UK,18+ years,general pop,54.8,53.3,56.3,,delta,~11 weeks
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,1-28,hospitalization,severe,UK,18+ years,general pop,78.2,75.2,80.8,,delta,~11 weeks
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,hospitalization,severe,UK,18+ years,general pop,83.9,80.0,87.1,,delta,~11 weeks
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,1-28,death,death,UK,18+ years,general pop,77.4,66.3,84.9,,delta,~11 weeks
91,Hulme,Retrospective cohort,06Jun2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,death,death,UK,18+ years,general pop,93.5,87.6,96.6,,delta,~11 weeks
103,Lee,Test-negative case-control,12Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated,84+,infection,infection,UK,cancer patients aged 18+,immunocompromised,58.3,57.7,58.9,,delta,~12 weeks
103,Lee,Test-negative case-control,12Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated,84+,symptomatic disease,symptomatic,UK,cancer patients aged 18+,immunocompromised,63.2,62.6,63.8,,delta,~12 weeks
103,Lee,Test-negative case-control,12Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated,84+,hospitalization,severe,UK,cancer patients aged 18+,immunocompromised,79.2,73.9,83.4,,delta,~12 weeks
103,Lee,Test-negative case-control,12Jul2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),included,unvaccinated,84+,death,death,UK,cancer patients aged 18+,immunocompromised,94.3,91.9,96.0,,delta,~12 weeks
123,Kim,Matched case-control,29Aug2022,AZD1222 (AstraZeneca),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of AZD1222,14+,infection,infection,South Korea,HCW,HCW,48.3,30.0,72.5,,omicron,~15 weeks
1,Bar-On,Retrospective cohort,07Oct2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,18+ years,general pop,92.0,90.0,93.0,,delta,3 weeks
1,Bar-On,Retrospective cohort,07Oct2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,12+,severe disease,severe,Israel,18+ years,general pop,94.0,91.0,96.0,,delta,3 weeks
2,Patalon,Test-negative case-control,30Nov2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,14-20,infection,infection,Israel,40+ years,40+ years,85.0,83.0,86.0,,delta,~7 weeks
2,Patalon,Test-negative case-control,30Nov2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,28-65,infection,infection,Israel,40+ years,40+ years,86.0,85.0,87.0,,delta,~7 weeks
2,Patalon,Matched case-control,30Nov2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,14-20,infection,infection,Israel,40+ years,40+ years,87.0,85.0,87.0,,delta,~7 weeks
2,Patalon,Matched case-control,30Nov2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,28-65,infection,infection,Israel,40+ years,40+ years,83.0,82.0,85.0,,delta,~7 weeks
2,Patalon,Matched case-control,30Nov2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,14-20,hospitalization,severe,Israel,40+ years,40+ years,92.0,87.0,95.0,,delta,~7 weeks
2,Patalon,Matched case-control,30Nov2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,28-65,hospitalization,severe,Israel,40+ years,40+ years,97.0,95.0,98.0,,delta,~7 weeks
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,16-29 years,16-29 years,94.2,93.6,94.9,,delta,~3.5 weeks
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,30-39 years,30-39 years,88.6,87.8,89.5,,delta,~4.5 weeks
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,40-49 years,40-49 years,89.7,89.1,90.4,,delta,5 weeks
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,50-59 years,50-59 years,91.8,91.2,92.4,,delta,6 weeks
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,12+,infection,infection,Israel,60+ years,60+ years,91.9,91.6,92.2,,delta,8 weeks
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,12+,severe disease,severe,Israel,40-59 years,40-59 years,95.4,90.6,97.8,,delta,6 weeks
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,12+,severe disease,severe,Israel,60+ years,60+ years,94.5,93.4,95.3,,delta,8 weeks
3,Bar-On,Retrospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,12+,death,death,Israel,60+ years,60+ years,93.2,89.4,95.7,,delta,8 weeks
5,Saciuk,Retrospective cohort,02Nov2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses,7+,infection,infection,Israel,18+ years,general pop,89.1,87.5,90.5,,delta,10 weeks
6,Barda,Retrospective cohort,29Oct2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,7+,infection,infection,Israel,18+ years,general pop,88.0,87.0,90.0,,delta,~7 weeks
6,Barda,Retrospective cohort,29Oct2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,7+,symptomatic disease,symptomatic,Israel,18+ years,general pop,91.0,89.0,92.0,,delta,~7 weeks
6,Barda,Retrospective cohort,29Oct2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,7+,hospitalization,severe,Israel,18+ years,general pop,93.0,88.0,97.0,,delta,~7 weeks
6,Barda,Retrospective cohort,29Oct2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,7+,severe disease,severe,Israel,18+ years,general pop,92.0,82.0,97.0,,delta,~7 weeks
6,Barda,Retrospective cohort,29Oct2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,7+,death,death,Israel,18+ years,general pop,81.0,59.0,97.0,,delta,~7 weeks
7,Andrews,Test-negative case-control,17Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses ≥140 days prior,14+,symptomatic disease,symptomatic,England,50+ years,≥ 50 years,84.5,83.7,85.3,,delta,~7.5 weeks
7,Andrews,Test-negative case-control,17Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,symptomatic disease,symptomatic,England,50+ years,≥ 50 years,94.3,93.9,94.6,,delta,~7.5 weeks
8,Sharma,Matched retrospective cohort,30Nov2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses ≥180 days prior,0+,infection,infection,USA,veterans,veterans,45.7,37.9,52.5,,delta,~7 weeks
8,Sharma,Matched retrospective cohort,30Nov2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses ≥180 days prior,0+,hospitalization,severe,USA,veterans,veterans,44.8,26.6,58.4,,delta,~7 weeks
9,Goldberg,Retrospective cohort,05Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,12+,infection,infection,Israel,16-39 years,16-39 years,91.0,90.1,91.3,,delta,~8 weeks
9,Goldberg,Retrospective cohort,05Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,12+,infection,infection,Israel,40-59 years,40-59 years,89.0,88.3,89.3,,delta,~8 weeks
9,Goldberg,Retrospective cohort,05Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,12+,infection,infection,Israel,60+ years,≥ 60 years,82.2,81.5,82.8,,delta,~8 weeks
10,Arbel,Prospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,14+,death,death,Israel,18+ years,general pop,33.0,26.0,40.0,,delta,~8 weeks
10,Arbel,Prospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,54+,death,death,Israel,18+ years,general pop,91.0,87.0,93.0,,delta,~8 weeks
10,Arbel,Prospective cohort,08Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,54+,infection,infection,Israel,18+ years,general pop,83.0,82.0,94.0,,delta,~8 weeks
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,18+ years,general pop,68.7,67.9,69.5,omicron,omicron,~14 weeks
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,10+ weeks,symptomatic disease,symptomatic,England,18+ years,general pop,50.1,49.0,51.2,omicron,omicron,~14 weeks
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,England,18+ years,general pop,95.2,94.9,95.5,delta,delta,~14 weeks
11,Andrews,Test-negative case-control,14Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,10+ weeks,symptomatic disease,symptomatic,England,18+ years,general pop,90.2,89.6,90.8,delta,delta,~14 weeks
12,Berec,Retrospective cohort,12Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses ≥6-8 months prior,7+,infection,infection,Czech Republic,18+ years,general pop,92.0,91.0,92.0,,delta,~8 weeks
13,Tartof,Retrospective matched cohort,14Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,infection,infection,USA,18+ years,general pop,88.0,86.0,89.0,delta,delta,~12 weeks
13,Tartof,Retrospective matched cohort,14Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,hospitalization,severe,USA,18+ years,general pop,97.0,95.0,98.0,delta,delta,~12 weeks
13,Tartof,Retrospective matched cohort,14Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses ≥6 months prior,14+,infection,infection,USA,18+ years,general pop,75.0,71.0,78.0,delta,delta,~12 weeks
13,Tartof,Retrospective matched cohort,14Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses ≥6 months prior,14+,hospitalization,severe,USA,18+ years,general pop,70.0,48.0,83.0,delta,delta,~12 weeks
14,Hansen,Retrospective cohort,23Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses in 60+ year olds,1-30,infection,infection,Denmark,60+ years,≥ 60 years,54.6,30.4,70.4,omicron,omicron,~4 weeks
14,Hansen,Retrospective cohort,23Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses in 60+ year olds,1-30,infection,infection,Denmark,60+ years,≥ 60 years,81.2,79.2,82.9,delta,delta,~4 weeks
15,Amir,Quasi-experimental,21Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses <60 days prior, 12-14 years of age",14+,infection,infection,Israel,16-18 years,16-18 years,73.4,67.1,78.9,,delta,~4 weeks
15,Amir,Quasi-experimental,21Dec2021,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals aged 16-18 years,14+,infection,infection,Israel,16-18 years,16-18 years,96.2,94.8,97.2,,delta,~4 weeks
16,Lustig,Prospective cohort,09May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,10+,infection,infection,Israel,HCW,HCW,85.6,79.2,90.1,,delta,~7 weeks
19,Tan,Retrospective cohort,11Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,infection,infection,Singapore,60+ years,≥ 60 years,73.0,71.0,74.0,,delta,~6 weeks
19,Tan,Retrospective cohort,11Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,symptomatic disease,symptomatic,Singapore,60+ years,≥ 60 years,72.0,71.0,74.0,,delta,~6 weeks
19,Tan,Retrospective cohort,11Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer),12+,severe disease,severe,Singapore,60+ years,≥ 60 years,95.0,92.0,97.0,,delta,~6 weeks
21,Spitzer,Prospective cohort,10Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥1 month prior,7+,infection,infection,Israel,HCW,HCW,93.0,80.0,98.0,,delta,~4 weeks
21,Spitzer,Prospective cohort,10Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥1 month prior,7+,symptomatic disease,symptomatic,Israel,HCW,HCW,93.0,75.0,98.0,,delta,~4 weeks
21,Spitzer,Prospective cohort,10Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥1 month prior,7+,asymptomatic infection,asymptomatic,Israel,HCW,HCW,92.0,52.0,99.0,,delta,~4 weeks
22,Waxman,Retrospective cohort,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥5 months prior,7+,hospitalization,severe,Israel,16+ years,general pop,89.0,87.0,91.0,,delta,~15.5 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,ED visit,symptomatic,USA,hospital admissions,general pop,75.0,70.0,79.0,omicron,omicron,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14 to <3 m,ED visit,symptomatic,USA,hospital admissions,general pop,77.0,72.0,81.0,omicron,omicron,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,3+ m,ED visit,symptomatic,USA,hospital admissions,general pop,53.0,36.0,66.0,omicron,omicron,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,hospitalization,severe,USA,hospital admissions,general pop,82.0,77.0,87.0,omicron,omicron,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14 to <3 m,hospitalization,severe,USA,hospital admissions,general pop,85.0,80.0,89.0,omicron,omicron,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,3+ m,hospitalization,severe,USA,hospital admissions,general pop,55.0,28.0,71.0,omicron,omicron,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,ED visit,symptomatic,USA,hospital admissions,general pop,83.0,79.0,86.0,delta,delta,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14 to <3 m,ED visit,symptomatic,USA,hospital admissions,general pop,84.0,80.0,87.0,delta,delta,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,3+ m,ED visit,symptomatic,USA,hospital admissions,general pop,72.0,58.0,82.0,delta,delta,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,hospitalization,severe,USA,hospital admissions,general pop,87.0,81.0,92.0,delta,delta,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14 to <3 m,hospitalization,severe,USA,hospital admissions,general pop,89.0,83.0,93.0,delta,delta,~23 weeks
25,Tartof,Test-negative case-control,22Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,3+ m,hospitalization,severe,USA,hospital admissions,general pop,71.0,40.0,86.0,delta,delta,~23 weeks
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination ≥6-8 months prior,7+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,49.4,47.1,51.6,omicron,omicron,~10 weeks
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination ≥6-8 months prior,14+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,49.9,47.6,52.2,omicron,omicron,~10 weeks
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination ≥6-8 months prior,7+,"severe, critical, or fatal disease",severe,Qatar,18+ years,general pop,76.5,55.9,87.5,omicron,omicron,~10 weeks
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination ≤8 months prior,7+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,38.0,28.8,46.0,omicron,omicron,~10 weeks
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination >8 months prior,7+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,50.5,48.2,52.8,omicron,omicron,~10 weeks
27,Abu-Raddad,Matched retrospective cohort,12May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥6-8 months prior,7+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,86.1,67.3,94.1,delta,delta,~10 weeks
28,Spensley,Prospective cohort,26Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,infection,infection,UK,end stage kidney disease patients,end stage kidney disease patients,66.0,36.0,81.0,omicron,omicron,~15 weeks
31,Willet,Test-negative case-control,26Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,infection,infection,Scotland,18+ years,general pop,43.2,38.1,47.8,omicron,omicron,~11 weeks
31,Willet,Test-negative case-control,26Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,infection,infection,Scotland,18+ years,general pop,85.9,84.2,87.4,delta,delta,~11 weeks
32,Lytras,Retrospective cohort,14Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,intubation,severe,Greece,15-79 years,15-79 years,98.2,97.2,98.9,,"non-VOC, alpha, & delta",~12 weeks
32,Lytras,Retrospective cohort,14Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,intubation,severe,Greece,80+ years,≥ 80 years,97.5,95.5,98.6,,"non-VOC, alpha, & delta",~12 weeks
32,Lytras,Retrospective cohort,14Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,death,death,Greece,15-79 years,15-79 years,98.3,96.9,99.1,,"non-VOC, alpha, & delta",~12 weeks
32,Lytras,Retrospective cohort,14Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,death,death,Greece,80+ years,≥ 80 years,98.4,97.4,99.0,,"non-VOC, alpha, & delta",~12 weeks
34,Bar-On,Prospective cohort,01Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 3 doses ≥4 months prior,12+,infection,infection,Israel,60+ years,≥ 60 years,50.0,50.0,53.0,,omicron,2 weeks
34,Bar-On,Prospective cohort,01Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 3 doses ≥4 months prior,12+,severe disease,severe,Israel,60+ years,≥ 60 years,77.0,59.0,87.0,,omicron,2 weeks
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,<1 month,symptomatic disease,symptomatic,Qatar,18+ years,general pop,59.9,51.2,67.0,omicron BA.1,omicron BA.1,~19 weeks
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,≥1 month,symptomatic disease,symptomatic,Qatar,18+ years,general pop,40.5,30.8,48.8,omicron BA.1,omicron BA.1,~19 weeks
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,<1 month,symptomatic disease,symptomatic,Qatar,18+ years,general pop,43.7,36.5,50.0,omicron BA.2,omicron BA.2,~19 weeks
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,≥1 month,symptomatic disease,symptomatic,Qatar,18+ years,general pop,40.2,34.2,45.7,omicron BA.2,omicron BA.2,~19 weeks
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,<1 month,symptomatic disease,symptomatic,Qatar,18+ years,general pop,49.5,44.3,54.1,omicron,omicron,~19 weeks
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,≥1 month,symptomatic disease,symptomatic,Qatar,18+ years,general pop,39.4,34.4,44.0,omicron,omicron,~19 weeks
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,1-6 weeks,"severe, critical, or fatal disease",severe,Qatar,18+ years,general pop,90.9,78.6,96.1,omicron,omicron,~19 weeks
37,Chemaitelly,Test-negative case-control,13Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,≥7 weeks,"severe, critical, or fatal disease",severe,Qatar,18+ years,general pop,90.9,78.6,96.1,omicron,omicron,~19 weeks
39,Hayek,Retrospective cohort,27Jan2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of primary mRNA series ≥5 months prior,7+,infection,infection,Israel,households with children,households with children,86.3,83.4,88.6,,delta,~11 weeks
43,Patalon,Test-negative case-control,09Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥5 months prior,1-51,infection,infection,Israel,18+ years,general pop,53.4,47.7,58.6,,omicron,~21 weeks
43,Patalon,Test-negative case-control,09Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥5 months prior,93-142,infection,infection,Israel,18+ years,general pop,3.6,0.6,6.5,,omicron,~21 weeks
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14-74,infection,infection,Czech Republic,18+ years,general pop,58.0,58.0,59.0,,omicron,~24 weeks
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,75+,infection,infection,Czech Republic,18+ years,general pop,24.0,22.0,26.0,,omicron,~24 weeks
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14-74,hospitalization,severe,Czech Republic,18+ years,general pop,86.0,84.0,89.0,,omicron,~24 weeks
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,75+,hospitalization,severe,Czech Republic,18+ years,general pop,79.0,74.0,82.0,,omicron,~24 weeks
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14-74,infection,infection,Czech Republic,18+ years,general pop,90.0,90.0,91.0,,delta,~24 weeks
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,75+,infection,infection,Czech Republic,18+ years,general pop,80.0,78.0,83.0,,delta,~24 weeks
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14-74,hospitalization,severe,Czech Republic,18+ years,general pop,98.0,97.0,98.0,,delta,~24 weeks
44,Šmíd,Retrospective cohort,25Feb2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,75+,hospitalization,severe,Czech Republic,18+ years,general pop,96.0,94.0,97.0,,delta,~24 weeks
45,Klein,Test-negative case-control,01Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,16-17 years,16-17 years,81.0,59.0,91.0,,omicron,~4 weeks
45,Klein,Test-negative case-control,01Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,7+,ED or UC visit,symptomatic,USA,16-17 years,16-17 years,86.0,73.0,93.0,,omicron or delta,~4 weeks
46,Norddahl,Retrospective cohort,01Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination 6 or more months prior,0+,infection,infection,Iceland,18-80 years,general pop,47.0,36.0,56.0,omicron,omicron,~4 weeks
46,Norddahl,Retrospective cohort,01Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination 6 or more months prior,0+,infection,infection,Iceland,18-80 years,general pop,52.0,28.0,69.0,delta,delta,~4 weeks
47,Butt,Retrospective cohort,04Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination 4.5 months prior,14+,symptomatic disease,symptomatic,USA,veterans,veterans,84.0,78.0,88.0,,delta,7 weeks
47,Butt,Retrospective cohort,04Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination 4.5 months prior,14+,hospitalization,severe,USA,veterans,veterans,77.0,65.0,85.0,,delta,7 weeks
49,Baum,Retrospective cohort,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,70+ years,≥ 70 years,95.0,94.0,96.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks
49,Baum,Retrospective cohort,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,70+ years,≥ 70 years,89.0,87.0,91.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks
49,Baum,Retrospective cohort,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14-60,ICU admission,severe,Finland,70+ years,≥ 70 years,98.0,95.0,99.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks
49,Baum,Retrospective cohort,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,61+,ICU admission,severe,Finland,70+ years,≥ 70 years,95.0,92.0,97.0,,"non-VOC, alpha, delta, & omicron",~20.5 weeks
49,Baum,Retrospective cohort,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,70+ years,≥ 70 years,96.0,93.0,97.0,,delta,~13 weeks
49,Baum,Retrospective cohort,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,70+ years,≥ 70 years,94.0,75.0,99.0,,delta,~13 weeks
49,Baum,Retrospective cohort,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14-60,hospitalization,severe,Finland,70+ years,≥ 70 years,94.0,92.0,95.0,,omicron,~20.5 weeks
49,Baum,Retrospective cohort,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,61+,hospitalization,severe,Finland,70+ years,≥ 70 years,87.0,85.0,89.0,,omicron,~20.5 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,74.4,63.4,82.2,omicron BA.1,omicron BA.1,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,18+ years,general pop,100.0,30.6,100.0,omicron BA.1,omicron BA.1,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,59.6,52.9,65.3,omicron BA.1,omicron BA.1,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,18+ years,general pop,97.5,71.7,99.8,omicron BA.1,omicron BA.1,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,77.3,72.4,81.4,omicron BA.2,omicron BA.2,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,18+ years,general pop,100.0,82.6,100.0,omicron BA.2,omicron BA.2,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,52.2,48.1,55.9,omicron BA.2,omicron BA.2,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,18+ years,general pop,98.2,91.9,99.6,omicron BA.2,omicron BA.2,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,76.3,71.7,80.1,omicron,omicron,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,18+ years,general pop,100.0,91.8,100.0,omicron,omicron,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,7+,symptomatic disease,symptomatic,Qatar,18+ years,general pop,54.0,50.4,57.3,omicron,omicron,~19 weeks
51,Altarawneh,Test-negative case-control,15Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,7+,hospitalization or death,severe,Qatar,18+ years,general pop,92.5,84.4,96.3,omicron,omicron,~19 weeks
53,Stowe,Test-negative case-control,24Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,7-13,hospitalization,severe,UK,18-64 years,18-64 years,79.0,68.0,83.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,105+,hospitalization,severe,UK,18-64 years,18-64 years,70.0,59.0,78.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14-28,ICU admission,severe,UK,18-64 years,18-64 years,99.0,90.0,100.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,70-98,ICU admission,severe,UK,18-64 years,18-64 years,89.0,74.0,96.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,7-13,hospitalization,severe,UK,65+ years,≥ 65 years,90.0,59.0,98.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,105+,hospitalization,severe,UK,65+ years,≥ 65 years,83.0,82.0,84.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,7-13,ICU admission,severe,UK,65+ years,≥ 65 years,94.0,10.0,99.0,,omicron,~22 weeks
53,Stowe,Test-negative case-control,24Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,105+,ICU admission,severe,UK,65+ years,≥ 65 years,82.0,70.0,90.0,,omicron,~22 weeks
58,Hansen,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14-30,infection,infection,Denmark,12+ years,general pop,47.9,47.4,48.2,,omicron,~2 weeks
58,Hansen,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,121+,infection,infection,Denmark,12+ years,general pop,40.5,38.9,42.2,,omicron,~20 weeks
58,Hansen,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14-30,hospitalization,severe,Denmark,12+ years,general pop,88.8,87.3,90.1,,omicron,~2 weeks
58,Hansen,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,121+,hospitalization,severe,Denmark,12+ years,general pop,66.2,61.1,70.7,,omicron,~20 weeks
61,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,7+,infection,infection,Norway,18+ years,general pop,75.3,72.5,77.8,,delta,~6.5 weeks
61,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,7+,hospitalization,severe,Norway,18+ years,general pop,95.6,93.1,97.2,,delta,~6.5 weeks
59,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,7+,infection,infection,Norway,18+ years,general pop,75.3,72.5,77.8,,delta,~6.5 weeks
59,Starrfelt,Retrospective cohort,30Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,7+,hospitalization,severe,Norway,18+ years,general pop,95.6,93.1,97.2,,delta,~6.5 weeks
60,Glatman-Freedman,Retrospective cohort,31Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,15-21,infection,infection,Israel,16-59 years,16-59 years,96.8,96.0,97.5,,delta & omicron,14 weeks
60,Glatman-Freedman,Retrospective cohort,31Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,106-112,infection,infection,Israel,16-59 years,16-59 years,77.6,68.4,84.2,,delta & omicron,14 weeks
60,Glatman-Freedman,Retrospective cohort,31Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,15-21,infection,infection,Israel,60+ years,≥ 60 years,93.1,91.8,94.2,,delta & omicron,18 weeks
60,Glatman-Freedman,Retrospective cohort,31Mar2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,134-140,infection,infection,Israel,60+ years,≥ 60 years,61.3,52.5,68.4,,delta & omicron,18 weeks
64,Buchan,Test-negative case-control,07Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,7+,symptomatic disease,symptomatic,Canada,12-17 years,12-17 years,62.0,49.0,72.0,omicron,omicron,~3 weeks
67,Institute of Public Health,Test-negative case-control,12Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14+,hospitalization,severe,Chile,18+ years,general pop,88.3,79.5,93.3,,gamma & delta,~24 weeks
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,"unvaccinated individuals, previously infected",14-69,symptomatic disease,symptomatic,Brazil,18+ years,general pop,56.4,53.7,59.0,,omicron,~28 weeks
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,"unvaccinated individuals, previously infected",70+,symptomatic disease,symptomatic,Brazil,18+ years,general pop,43.3,25.8,56.6,,omicron,~28 weeks
69,Cerqueira-Silva ,Test-negative case-control,01Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,"unvaccinated individuals, previously infected",14-69,hospitalization or death,severe,Brazil,18+ years,general pop,75.0,53.3,86.7,,omicron,~28 weeks
69,Cerqueira-Silva ,Matched case-control,01Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,"unvaccinated individuals, previously infected",14-69,symptomatic disease,symptomatic,Brazil,18+ years,general pop,58.1,55.3,60.6,,omicron,~28 weeks
69,Cerqueira-Silva ,Matched case-control,01Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,"unvaccinated individuals, previously infected",70+,symptomatic disease,symptomatic,Brazil,18+ years,general pop,29.8,3.3,49.0,,omicron,~28 weeks
69,Cerqueira-Silva ,Matched case-control,01Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),previously infected only,"unvaccinated individuals, previously infected",14-69,hospitalization or death,severe,Brazil,18+ years,general pop,85.2,55.7,95.1,,omicron,~28 weeks
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14-120,infection,infection,Hungary,18-64 years,18-64 years,82.2,81.5,82.8,,delta,~20 weeks
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14-120,hospitalization,severe,Hungary,18-64 years,18-64 years,94.3,93.3,95.1,,delta,~20 weeks
72,Vokó,Retrospective cohort,22Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14-120,death,death,Hungary,18-64 years,18-64 years,96.8,95.2,97.9,,delta,~20 weeks
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,0+,infection,infection,Canada,LTCF residents aged 60+ years,LTCF residents,32.0,24.0,38.0,omicron,omicron,~34 weeks
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,0+,symptomatic disease,symptomatic,Canada,LTCF residents aged 60+ years,LTCF residents,53.0,39.0,63.0,omicron,omicron,~34 weeks
73,Grewal,Test-negative case-control,06Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,0+,hospitalization or death,severe,Canada,LTCF residents aged 60+ years,LTCF residents,77.0,67.0,83.0,omicron,omicron,~34 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,Brazil,18+ years,general pop,35.2,33.7,36.7,,omicron,2 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,9-12 weeks,symptomatic disease,symptomatic,Brazil,18+ years,general pop,36.3,29.9,42.2,,omicron,10 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,severe disease,severe,Brazil,18+ years,general pop,88.3,85.1,90.7,,omicron,2 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,9-12 weeks,severe disease,severe,Brazil,18+ years,general pop,82.5,64.0,91.5,,omicron,10 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,symptomatic disease,symptomatic,Scotland,18+ years,general pop,52.9,49.3,56.3,,omicron,2 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,13+ weeks,symptomatic disease,symptomatic,Scotland,18+ years,general pop,30.1,23.5,36.1,,omicron,~22 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,2-4 weeks,severe disease,severe,Scotland,18+ years,general pop,81.6,29.9,95.2,,omicron,2 weeks
77,Cerqueira-Silva ,Test-negative case-control,14Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,13+ weeks,severe disease,severe,Scotland,18+ years,general pop,75.7,33.9,91.0,,omicron,~22 weeks
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,14+,infection,infection,USA,veterans,veterans,30.1,26.2,33.7,,omicron,~27 weeks
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,14+,hospitalization,severe,USA,veterans,veterans,61.4,55.0,67.1,,omicron,~27 weeks
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses ≥5 months prior,14+,death,death,USA,veterans,veterans,78.8,67.9,87.5,,omicron,~27 weeks
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14+,infection,infection,USA,veterans,veterans,47.8,45.2,50.3,,omicron,~27 weeks
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14+,hospitalization,severe,USA,veterans,veterans,81.8,79.2,84.2,,omicron,~27 weeks
79,Sharma,Matched case-control,27Apr2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14+,death,death,USA,veterans,veterans,89.6,85.0,93.6,,omicron,~27 weeks
81,Suah,Test-negative case-control,02May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),unknown,complete vaccination with 2 doses of BNT162b2 (Pfizer) 4-6 months prior,14+,infection,infection,Malaysia,18+ years,general pop,52.0,50.3,51.9,,omicron,~12 weeks
81,Suah,Test-negative case-control,02May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),unknown,complete vaccination with 2 doses of BNT162b2 (Pfizer) 4-6 months prior,14+,infection,infection,Malaysia,18+ years,general pop,89.4,89.2,89.7,,delta,~12 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",7+,infection,infection,USA,veterans 21+,general pop,11.0,7.0,14.0,,omicron,~19.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",<28,infection,infection,USA,veterans 21+,general pop,30.0,23.0,36.0,,omicron,~19.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",84+,infection,infection,USA,veterans 21+,general pop,-9.0,-22.0,2.0,,omicron,~19.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",7+,hospitalization,severe,USA,veterans 21+,general pop,50.0,41.0,57.0,,omicron,~19.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",<28,hospitalization,severe,USA,veterans 21+,general pop,62.0,43.0,75.0,,omicron,~19.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",84+,hospitalization,severe,USA,veterans 21+,general pop,45.0,18.0,63.0,,omicron,~19.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",7+,ICU admission or death,severe,USA,veterans 21+,general pop,88.0,68.0,96.0,,omicron,~19.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",28-56,ICU admission or death,severe,USA,veterans 21+,general pop,90.0,22.0,99.0,,omicron,~19.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",84+,ICU admission or death,severe,USA,veterans 21+,general pop,79.0,-78.0,98.0,,omicron,~19.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",,infection,infection,USA,veterans 21+,general pop,73.0,70.0,76.0,,delta,~9.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",,hospitalization,severe,USA,veterans 21+,general pop,79.0,71.0,85.0,,delta,~9.5 weeks
83,Butt,Retrospective cohort,03May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,"complete vaccination with 2 doses of BNT162b2 (Pfizer) by April 30, 2021",,ICU admission or death,severe,USA,veterans 21+,general pop,90.0,21.0,99.0,,delta,~9.5 weeks
84,Amir,Retrospective cohort,05May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥4 months prior,0-30,hospitalization or death,severe,Israel,60+ years,≥ 60 years,57.0,37.5,71.0,,omicron,~31 weeks
84,Amir,Retrospective cohort,05May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥4 months prior,180-210,hospitalization or death,severe,Israel,60+ years,≥ 60 years,67.8,59.0,75.6,,omicron,~31 weeks
85,Rennert,Propensity matched case control,07May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,7+,infection,infection,USA,18+ years,general pop,42.8,22.7,57.6,,omicron,~16 weeks
85,Rennert,Propensity matched case control,07May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,7+,infection,infection,USA,18-65 years,18-65 years,74.3,42.1,88.6,,omicron,~16 weeks
87,Amir,Retrospective cohort,25May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,14-60,infection,infection,Israel,12-15 years,12-15 years,80.0,76.7,83.1,,omicron,~7 weeks
87,Amir,Retrospective cohort,25May2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses 120+ days prior,14-60,infection,infection,Israel,12-15 years,12-15 years,76.2,72.2,79.6,,omicron,~7 weeks
91,Hulme,Retrospective cohort,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,1-28,infection,infection,UK,18+ years,general pop,49.6,48.3,50.8,,delta,~11 weeks
91,Hulme,Retrospective cohort,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,infection,infection,UK,18+ years,general pop,49.7,47.8,51.5,,delta,~11 weeks
91,Hulme,Retrospective cohort,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,1-28,hospitalization,severe,UK,18+ years,general pop,73.8,68.9,77.9,,delta,~11 weeks
91,Hulme,Retrospective cohort,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,hospitalization,severe,UK,18+ years,general pop,86.1,81.9,89.4,,delta,~11 weeks
91,Hulme,Retrospective cohort,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,complete vaccination with 2 doses of AZD1222 or BNT162b2,29-70,death,death,UK,18+ years,general pop,92.6,86.5,96.0,,delta,~11 weeks
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) within last 6 months,14+,symptomatic disease,symptomatic,USA,HCW,HCW,78.0,63.0,87.0,,delta,~32 weeks
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) within last 6 months,14+,symptomatic disease,symptomatic,USA,HCW,HCW,50.0,42.0,56.0,,omicron,~32 weeks
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) within last 6 months,<56,symptomatic disease,symptomatic,USA,HCW,HCW,66.0,51.0,76.0,,omicron,~32 weeks
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) within last 6 months,112+,symptomatic disease,symptomatic,USA,HCW,HCW,55.0,19.0,76.0,,omicron,~32 weeks
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,HCW,HCW,93.0,78.0,98.0,,delta,~32 weeks
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,14+,symptomatic disease,symptomatic,USA,HCW,HCW,54.0,23.0,73.0,,omicron,~32 weeks
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,<56,symptomatic disease,symptomatic,USA,HCW,HCW,75.0,50.0,87.0,,omicron,~32 weeks
92,Richterman,Test-negative case-control,06Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated individuals,112+,symptomatic disease,symptomatic,USA,HCW,HCW,55.0,5.0,69.0,,omicron,~32 weeks
93,Adams,Prospective test-negative case control,14Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated individuals,7+,hospitalization,severe,USA,hospitalized adults,general pop,80.0,73.0,85.0,omicron,omicron,~39 weeks
95,Liu,Prospective cohort,21Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination 8-89 days prior,8+,hospitalization or death,severe,Australia,50-69 years,50-69 years,49.4,30.8,63.0,,omicron,~13 weeks
98,Ionescu,Test-negative case-control,28Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,infection,infection,Canada (Quebec),12-17 years,12-17 years,60.8,40.8,74.1,,omicron,~26 weeks
98,Ionescu,Test-negative case-control,28Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,infection,infection,Canada (British Colombia),12-17 years,12-17 years,63.7,41.1,77.7,,omicron,~26 weeks
100,Tartof,Test-negative case-control,30Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,<3 months,hospitalization,severe,USA,18+ years,general pop,80.0,74.0,84.0,omicron BA.1,omicron BA.1,
100,Tartof,Test-negative case-control,30Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,≥3 months,hospitalization,severe,USA,18+ years,general pop,76.0,69.0,82.0,omicron BA.1,omicron BA.1,~29 weeks
100,Tartof,Test-negative case-control,30Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,<3 months,ED admissions,symptomatic,USA,18+ years,general pop,74.0,69.0,78.0,omicron BA.1,omicron BA.1,
100,Tartof,Test-negative case-control,30Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,≥3 months,ED admissions,symptomatic,USA,18+ years,general pop,65.0,56.0,73.0,omicron BA.1,omicron BA.1,~29 weeks
100,Tartof,Test-negative case-control,30Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,<3 months,hospitalization,severe,USA,18+ years,general pop,74.0,47.0,87.0,omicron BA.2,omicron BA.2,
100,Tartof,Test-negative case-control,30Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,≥3 months,hospitalization,severe,USA,18+ years,general pop,70.0,53.0,81.0,omicron BA.2,omicron BA.2,~29 weeks
100,Tartof,Test-negative case-control,30Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,<3 months,ED admissions,symptomatic,USA,18+ years,general pop,59.0,40.0,72.0,omicron BA.2,omicron BA.2,
100,Tartof,Test-negative case-control,30Jun2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,≥3 months,ED admissions,symptomatic,USA,18+ years,general pop,5.0,-21.0,25.0,omicron BA.2,omicron BA.2,~29 weeks
101,Muhsen,Prospective cohort,01Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination at least 5 months prior,7+,infection,infection,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,89.0,85.0,93.0,,delta,~10 weeks
101,Muhsen,Prospective cohort,01Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination at least 5 months prior,7+,mild-moderate hospitalization,severe,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,93.0,86.0,97.0,,delta,~10 weeks
101,Muhsen,Prospective cohort,01Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination at least 5 months prior,7+,severe hospitalization,severe,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,90.0,76.0,96.0,,delta,~10 weeks
101,Muhsen,Prospective cohort,01Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination at least 5 months prior,7+,death,death,Israel,LTCF residents aged 60+ years,LTCF residents ≥ 60 years,96.0,84.0,99.1,,delta,~10 weeks
102,Guedalia,Retrospective cohort,11Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination at least 5 months prior,0+,hospitalization,severe,Israel,pregnant women aged 16+,pregnant women,48.0,37.0,57.0,,omicron BA.1,~31 weeks
102,Guedalia,Retrospective cohort,11Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination at least 5 months prior,0+,hospitalization with moderate disease,severe,Israel,pregnant women aged 16+,pregnant women,92.0,26.0,99.0,,omicron BA.1,~31 weeks
102,Guedalia,Retrospective cohort,11Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,0+,hospitalization,severe,Israel,pregnant women aged 16+,pregnant women,43.0,31.0,53.0,,omicron BA.1,~31 weeks
102,Guedalia,Retrospective cohort,11Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,0+,hospitalization with moderate disease,severe,Israel,pregnant women aged 16+,pregnant women,97.0,72.0,100.0,,omicron BA.1,~31 weeks
102,Guedalia,Retrospective cohort,11Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,0+,severe disease,severe,Israel,pregnant women aged 16+,pregnant women,94.0,43.0,99.0,,omicron BA.1,~31 weeks
102,Guedalia,Retrospective cohort,11Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination at least 5 months prior,0+,hospitalization,severe,Israel,pregnant women aged 16+,pregnant women,92.0,83.0,96.0,,delta,~15.5 weeks
102,Guedalia,Retrospective cohort,11Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,0+,hospitalization,severe,Israel,pregnant women aged 16+,pregnant women,97.0,95.0,99.0,,delta,~15.5 weeks
102,Guedalia,Retrospective cohort,11Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,0+,hospitalization with moderate disease,severe,Israel,pregnant women aged 16+,pregnant women,99.0,93.0,100.0,,delta,~15.5 weeks
102,Guedalia,Retrospective cohort,11Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,0+,severe disease,severe,Israel,pregnant women aged 16+,pregnant women,99.0,89.0,100.0,,delta,~15.5 weeks
103,Lee,Test-negative case-control,12Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,84+,infection,infection,UK,cancer patients aged 18+,immunocompromised,59.3,58.8,59.8,,delta,~12 weeks
103,Lee,Test-negative case-control,12Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,84+,symptomatic disease,symptomatic,UK,cancer patients aged 18+,immunocompromised,61.9,61.4,62.4,,delta,~12 weeks
103,Lee,Test-negative case-control,12Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,84+,hospitalization,severe,UK,cancer patients aged 18+,immunocompromised,81.1,76.8,84.6,,delta,~12 weeks
103,Lee,Test-negative case-control,12Jul2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,84+,death,death,UK,cancer patients aged 18+,immunocompromised,94.6,92.6,96.1,,delta,~12 weeks
108,Tartof,Test-negative case-control,03Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,14+,ED or UC visit,symptomatic,USA,12-17 years,12-17 years,87.0,72.0,94.0,omicron,omicron,~10 weeks
108,Tartof,Test-negative case-control,03Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,ED or UC visit,symptomatic,USA,12-17 years,12-17 years,87.0,71.0,95.0,omicron,omicron,~10 weeks
109,Pinto-Álvarez,Nested cohort,06Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,15+,infection,infection,Colombia,16+,general pop,72.5,59.5,81.4,,"mu, delta, & omicron",~26 weeks
109,Pinto-Álvarez,Nested cohort,06Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,15+,hospitalization,severe,Colombia,16+,general pop,82.9,63.5,92.1,,"mu, delta, & omicron",~26 weeks
109,Pinto-Álvarez,Nested cohort,06Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,15+,death,death,Colombia,16+,general pop,89.8,73.7,96.1,,"mu, delta, & omicron",~26 weeks
111,Low,Retrospective cohort,10Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of BNT162b2 (Pfizer) ≥3 months prior,14+,symptomatic disease,symptomatic,Malaysia,18+ years,general pop,99.0,99.0,100.0,,delta,~14 weeks
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,7+,infection,infection,USA,immunocompromised adults,immunocompromised adults,50.0,31.0,64.0,,omicron,~22 weeks
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,7+,infection,infection,USA,immunocompetent adults,general pop,35.0,29.0,41.0,,omicron,~22 weeks
112,Risk,Retrospective cohort,16Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,7+,hospitalization,severe,USA,18+ years,general pop,89.0,84.0,93.0,,omicron,~22 weeks
113,Kim,Retrospective cohort,17Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14-29,infection,infection,South Korea,12-18 years,12-18 years,56.3,50.0,61.7,,delta & omicron,~6 weeks
113,Kim,Retrospective cohort,17Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,30-59,infection,infection,South Korea,12-18 years,12-18 years,55.2,47.3,61.9,,delta & omicron,~6 weeks
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,severe disease,severe,"Hong Kong, SAR",18-50 years,18-50 years,76.1,24.8,92.4,,omicron BA.2,18 weeks
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,severe disease,severe,"Hong Kong, SAR",51-64 years,51-64 years,90.5,72.6,96.7,,omicron BA.2,18 weeks
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,severe disease,severe,"Hong Kong, SAR",65+ years,≥ 65 years,86.7,74.8,93.0,,omicron BA.2,18 weeks
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,death,death,"Hong Kong, SAR",18-50 years,18-50 years,82.1,35.5,95.0,,omicron BA.2,18 weeks
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,death,death,"Hong Kong, SAR",51-64 years,51-64 years,98.1,92.3,99.5,,omicron BA.2,18 weeks
114,Yan,Case-control,18Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,death,death,"Hong Kong, SAR",65+ years,≥ 65 years,97.5,95.1,98.7,,omicron BA.2,18 weeks
116,Cheng,Retrospective cohort,11Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,infection,infection,"Hong Kong, SAR",≥18 years with chronic kidney disease,≥18 years with chronic kidney disease,77.0,72.0,82.0,,omicron,~45 weeks
116,Cheng,Retrospective cohort,11Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,hospitalization,severe,"Hong Kong, SAR",≥18 years with chronic kidney disease,≥18 years with chronic kidney disease,85.0,73.0,92.0,,omicron,~45 weeks
116,Cheng,Retrospective cohort,11Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,death,death,"Hong Kong, SAR",≥18 years with chronic kidney disease,≥18 years with chronic kidney disease,95.0,78.0,99.0,,omicron,~45 weeks
117,Wan,Case-control,17Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,infection,infection,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,54.2,52.4,55.9,,omicron BA.2,~23 weeks
117,Wan,Case-control,17Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,hospitalization,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,91.4,89.5,92.9,,omicron BA.2,~23 weeks
117,Wan,Case-control,17Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,ICU admission,severe,"Hong Kong, SAR",≥12 years with diabetes mellitus,≥12 years with diabetes mellitus,86.3,71.5,93.4,,omicron BA.2,~23 weeks
118,Tsang,Prospective cohort,25Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,infection,infection,"Hong Kong, SAR",≥ 5 years,≥ 5 years,41.4,23.2,55.2,,omicron BA.2,~25 weeks
118,Tsang,Prospective cohort,25Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14+,symptomatic disease,symptomatic,"Hong Kong, SAR",≥ 5 years,≥ 5 years,50.9,31.0,65.0,,omicron BA.2,~25 weeks
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,15-60,infection,infection,Singapore,≥ 30 years,≥ 30 years,31.7,30.0,33.4,,omicron,~45 weeks
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,121-330,infection,infection,Singapore,≥ 30 years,≥ 30 years,-2.8,-5.4,0.3,,omicron,~45 weeks
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,15-60,severe disease,severe,Singapore,≥ 30 years,≥ 30 years,85.2,80.2,88.9,,omicron,~45 weeks
119,Ng,Retrospective cohort,26Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,complete vaccination with 2 doses of any mRNA vaccine 5 months prior,121-330,severe disease,severe,Singapore,≥ 30 years,≥ 30 years,87.3,84.2,89.8,,omicron,~45 weeks
120,Cocchio,Retrospective cohort,20Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,14-34,infection,infection,Italy,12-17 years,12-17 years,72.0,70.0,73.0,,omicron,~15 weeks
120,Cocchio,Retrospective cohort,20Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),excluded,unvaccinated,35-69,infection,infection,Italy,12-17 years,12-17 years,30.0,27.0,33.0,,omicron,~15 weeks
122,Barraza,Retrospective cohort,05Aug2022,BNT162b2 (Pfizer),BNT162b2 (Pfizer),included,unvaccinated,14+,infection,infection,Chile,18+ years,general pop,84.0,71.0,91.2,,"gamma, delta & omicron",~41 weeks
